Search the Newsreel

Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Crescent Biopharma Ord Shs (CBIO), detailing analyst ratings, price targets, and expected EPS and revenue figures. Based on 9 analysts, CBIO has a "Buy" rating with an average target price of $30.60, representing an 86.24% upside. The …

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)

Analysts from Stifel Nicolaus have issued bullish sentiments on Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO). Dyne Therapeutics received a Buy rating with a $37.00 price target, and Crescent Biopharma also received a Buy rating with a $28.00 price target, both indicating significant upside …

CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026)

This article details an SEC filing by CRESCENT BIOPHARMA, INC. (CBIO) on August 3, 2026, which is a Notice of Effectiveness for a POS AM submission. The filing indicates an effectiveness date of July 31, 2026, and provides key company and filing identification numbers. …

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma announced that its Board's Compensation Committee approved the grant of options to purchase 19,425 shares to a non-executive employee as an inducement award. These options were granted on July 31, 2026, with a 10-year term and an exercise price of $14.47, vesting …

Crescent expects trial data in 2027 after $143.7M offering

Crescent Biopharma reported a Q2 2026 net loss of $24.8 million but extended its cash runway into the second half of 2028 after a $143.7 million public offering in July 2026. The company anticipates multiple key clinical data readouts across its oncology pipeline in …

CBIO: Cash runway extended to 2028 as global oncology trials progress toward key 2027 data

Crescent Biopharma (CBIO) has extended its cash runway into the second half of 2028 following a $143.7 million public offering. The company is advancing enrollment in multiple global oncology trials, with key data readouts anticipated in 2027. R&D expenses have increased to support the …

CBIO Q2'26 Earnings: EPS estimate is (0.74) USD

Crescent Biopharma, Inc. (CBIO) is scheduled to release its Q2'26 earnings on July 30, with an estimated revenue of $357.14 thousand and an anticipated EPS of ($0.74). The article provides a table of historical and estimated revenue and EPS figures, along with surprise percentages …

CRESCENT BIOPHARMA, INC. 2026: Revenue $0 Net income ($24.84M), EPS ($0.74) — 10-Q Summary

Crescent Biopharma, Inc. (CBIO) reported a net loss of ($24.84M) for the 2026 quarter with no revenue, an increase from ($21.79M) in the prior-year quarter. Diluted loss per share improved significantly to ($0.74) from ($4.93) a year earlier, representing an 85% change. The company …

Crescent Biopharma (CBIO) Gets a Buy from Wedbush

Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003

Crescent Biopharma announced its Q2 2026 financial results and provided updates on its clinical pipeline, including CR-001, CR-002, and CR-003. The company is progressing enrollment in the ASCEND Phase 1/2 trial for CR-001 and anticipates key clinical data readouts starting in Q1 2027. Crescent …

Jiangsu Recbio Flags Narrowed First-Half Loss as Clinical Spend Eases

Crescent Biopharma: Q2 Earnings Snapshot

Crescent Biopharma (CBIO) reported a Q2 loss of $24.8 million, or 74 cents per share, missing Wall Street expectations of a 70-cent loss. This financial update was generated by Automated Insights using data from Zacks Investment Research.

Crescent Biopharma (NASDAQ: CBIO) registers 18.2M shares for investor resale

Crescent Biopharma (NASDAQ: CBIO) has filed a post-effective amendment to convert an existing Form S-1 into a Form S-3 shelf registration, allowing for the resale of up to 18,154,836 Ordinary Shares by existing investors. These shares include those from a December 2025 private placement, …

Crescent Biopharma Files Prospectus Supplement Reflecting Q2 2026 Financials and Share Resale Update

Crescent Biopharma, Inc. has filed a prospectus supplement on July 30, 2026, updating its securities registration to include the company's Q2 2026 financial results, which ended on June 30, 2026. The update also reflects the resale of approximately 19.6 million ordinary shares by existing …

Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update

Crescent Biopharma, Inc. released its financial results for the second quarter ended June 30, 2026, on July 30, 2026. The biopharmaceutical company submitted a formal disclosure to the Securities and Exchange Commission detailing its operational and financial metrics. This announcement highlights the company's ongoing …

Crescent Biopharma reports Q2 2026 net loss $24.8M, cash $171.6M and $143.7M public offering

Crescent Biopharma reported a net loss of $24.8 million for Q2 2026, an increase from $21.8 million in Q2 2025. The company held $171.6 million in cash and cash equivalents as of June 30, 2026, which increased to a pro forma $305.1 million after …

Crescent Biopharma reports Q2 2026 results, advances cancer drug trials, and raises $143.7M to fund operations through 2028

Crescent Biopharma announced its second quarter 2026 financial results, highlighting significant progress in clinical trials for its cancer therapies, including CR-001, CR-002, and CR-003, with key data anticipated from Q1 2027. The company successfully completed a $143.7 million public offering, extending its cash runway …

Crescent Biopharma posts $24.8 million Q2 net loss

Crescent Biopharma (CBIO) reported a net loss of $24.8 million, or $0.74 per basic and diluted share, for the second quarter of 2026. The company is advancing its clinical pipeline, including continued enrollment in the ASCEND Phase 1/2 trial for CR-001 and other trials …

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma reported its second-quarter 2026 financial results, highlighting significant progress in its clinical trials for CR-001, CR-002, and CR-003, with multiple data readouts anticipated in 2027. The company recently completed a $143.7 million public offering, extending its cash runway into the second half …

ADAR1 Capital Management LLC Sells 555,727 Shares of Crescent Biopharma, Inc. $CBIO

Crescent Biopharma (NASDAQ:CBIO) Issues Earnings Results, Misses Estimates By $0.04 EPS

Crescent Biopharma (Nasdaq: CBIO) posts Q2 loss, extends cash runway to 2028

Crescent Biopharma (Nasdaq:CBIO) - Stock Analysis

Crescent Biopharma (Nasdaq:CBIO) is a biotechnology company focused on developing cancer therapies. The company, with a market cap of US$610.4m, recently completed a follow-on equity offering and is advancing its pipeline candidates CR-001 (a PD-1 x VEGF bispecific antibody) and CR-003 (an ITGB6-targeted ADC) …

CBIO|Crescent Biopharma Ord Shs|Price:16.510|Chg%:-0.420

This article provides a detailed financial overview of Crescent Biopharma Ord Shs (CBIO), including its current stock price, market capitalization, key figures, and historical performance. It also features analyst ratings, indicating a "Buy" consensus with a target price of $31.00, and lists major shareholders. …

Exome Asset Management LLC Makes New $2.81 Million Investment in Crescent Biopharma, Inc. $CBIO

Crescent Biopharma Market Sentiment

This article provides a market sentiment analysis for Crescent Biopharma (CBIO), detailing analyst consensus, short interest, options flow, and insider activity. Key signals show a "Buy" analyst consensus, a rising short interest of 30.4%, bullish options flow with a 0.50 Put/Call ratio, and net …

CBIO Q1 2026 Earnings: Narrower Loss Surprises Analysts as Cash Management Improves - Dividend Earnings Report

Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts

Analysts have given Crescent Biopharma, Inc. (NASDAQ:CBIO) a consensus "Moderate Buy" rating with an average 12-month price target of $29.40. The company recently surpassed earnings expectations, reporting a loss of $0.70 per share against an anticipated $0.85 loss and revenue of $1.04 million versus …

Jennison Associates LLC Invests $2.81 Million in Crescent Biopharma, Inc. $CBIO

Jennison Associates LLC has acquired a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO) during the first quarter, purchasing 152,974 shares valued at approximately $2.81 million. Crescent Biopharma recently reported stronger-than-expected quarterly earnings and revenue. Despite recent insider stock sales to cover tax obligations, analysts …

Two Crescent Biopharma Employees Receive 52,500 Stock Options

Crescent Biopharma (Nasdaq: CBIO) announced that its independent Compensation Committee approved equity inducement awards for two non-executive employees, consisting of options to purchase an aggregate of 52,500 ordinary shares. These options have a 10-year term, an exercise price of $15.83, and will vest over …

Crescent Biopharma grants inducement stock options for 52,500 shares at $15.83 each

Crescent Biopharma has issued inducement equity awards to two new non-executive employees, granting options for a total of 52,500 ordinary shares. These options have a 10-year term and are priced at $15.83 per share, aligning with Nasdaq's closing price on July 22, 2026. The …

Crescent Biopharma (CBIO) Expected to Post Quarterly Earnings on Thursday

CBIO Options Chain — NASDAQ:CBIO

This article provides an options chain overview for Crescent Biopharma, Inc. (NASDAQ:CBIO). It outlines how users can track market movements, evaluate risks, and monitor live pricing, Greeks, and implied volatility for call and put options. The options data helps users build their own trading …